Table 2 Correlation between FAM64A expression and the clinicopathological characters of patients with prostate cancer (TCGA).
From: FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer
Clinico-pathologic variables | No. of cases | FAM64a expression | X2 | P | |
|---|---|---|---|---|---|
Low | High | ||||
All cases | 499 | 249 (44.3%) | 250 (55.7%) | ||
Age | |||||
≤60 | 224 (44.9%) | 122 (24.5%) | 102 (20.4%) | 3.3871 | 0.0657 |
>60 | 275 (45.1%) | 127 (25.4%) | 148 (29.7%) | ||
Clinical stage | |||||
T1–T2 | 350 (86.6%) | 188 (46.5%) | 162 (40.1%) | 10.861 | 0.0010*** |
T3–T4 | 54 (13.4%) | 16 (4.0%) | 38 (9.4%) | ||
Lymph nodes status | |||||
Negative | 328 (80.4%) | 161 (39.5%) | 167 (40.9%) | 5.1321 | 0.0235* |
Positive | 80 (19.6%) | 28 (6.9%) | 52 (12.7%) | ||
Gleason score | |||||
6–7 | 295 (59.1%) | 176 (35.3%) | 119 (23.8%) | 27.501 | <0.0001*** |
8–10 | 204 (40.9%) | 73 (14.6%) | 131 (26.3%) | ||
PSA | |||||
− | 429 (96.6%) | 213 (48.0%) | 216 (48.6%) | 0.6210 | 0.4307 |
+ | 15 (3.4%) | 9 (2.0%) | 6 (1.4%) | ||
Survival times (years) | |||||
≤5 | 414 (83%) | 217 (43.5%) | 197 (39.5%) | 6.1521 | 0.0131* |
>5 | 85 (17%) | 32 (6.4%) | 53 (10.6%) | ||
